Oncolytics Insider Buy Signals Growth After FDA Fast‑Track Approval
Oncolytics insider buys reveal confidence after FDA Fast‑Track approval; investor insight on potential $200‑$400 M revenue and cautious strategy.
4 minutes to read
Oncolytics Biotech Inc
Oncolytics Insider Buy Signals Strong Confidence in Reovirus Pipeline and Nevada Shift
Oncolytics Biotech insider buying shows long‑term confidence in its reovirus platform, regulatory shift to Nevada, and patent expansion—signals to watch for future upside.
4 minutes to read